sorafenib has been researched along with Spinal Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bulman, M; Evans, DGR; Freemont, AJ; Linder, C; Mangham, DC; Smith, MJ; Wallace, A | 1 |
| Alexandrescu, DT; Dasanu, CA; Dutcher, J | 1 |
1 review(s) available for sorafenib and Spinal Neoplasms
| Article | Year |
|---|---|
Sarcoma in neurofibromatosis 2: case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Delayed Diagnosis; Diagnosis, Differential; Doxorubicin; Fatal Outcome; Humans; Male; Neoplasm Grading; Neurofibromatosis 2; Neurofibromin 2; Palliative Care; Retroperitoneal Neoplasms; Sarcoma; SMARCB1 Protein; Sorafenib; Spinal Neoplasms; Young Adult | 2019 |
1 other study(ies) available for sorafenib and Spinal Neoplasms
| Article | Year |
|---|---|
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms | 2007 |